- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | OmniAb, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | OmniAb, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | OmniAb Reports First Quarter 2024 Financial Results and Business Highlights | 176 | Business Wire | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
"The... ► Artikel lesen | |
| 26.03. | Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying | 1 | Benzinga.com | ||
| 25.03. | OmniAb, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | OmniAb CEO acquires $1.17m in company stock | 1 | Investing.com | ||
| 21.03. | OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 21.03. | Earnings call: OmniAb reports growth and expansion despite Q4 revenue dip | 1 | Investing.com | ||
| 20.03. | OmniAb Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 20.03. | Recap: OmniAb Q4 Earnings | 1 | Benzinga.com | ||
| 20.03. | OmniAb, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | 115 | Business Wire | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program... ► Artikel lesen | |
| 08.12.23 | OmniAb files for $300M mixed shelf | 1 | Seeking Alpha | ||
| 09.11.23 | OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights | 314 | Business Wire | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program... ► Artikel lesen | |
| 10.08.23 | OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights | 446 | Business Wire | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.
"Our... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 26,030 | +0,08 % | Pfizer nach Zahlen und Kurssprung: Das raten jetzt die Analysten | Der Pharma-Riese Pfizer hat in dieser Handelswoche mit seinen Zahlen zum ersten Quartal die Anleger überzeugt. Die Aktie konnte sich daraufhin von den jüngsten Tiefständen etwas nach oben lösen. DER... ► Artikel lesen | |
| GILEAD SCIENCES | 61,26 | +0,08 % | Gilead Sciences Aktie: Biotechstrukturen im Wandel | Die vergangene Woche war für den Biotech-Sektor besonders ereignisreich: Übernahmen und Gewinnberichte führten zu starken Veränderungen. Im Fokus standen die Ergebnisse von Gilead Sciences und GSK plc... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 392,30 | -0,08 % | Vertex Pharmaceuticals Inc. Q1 Profit Increases, beats estimates | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for its first quarter that increased from last year and beat the Street estimates.The company's bottom... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 11,155 | -0,54 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy | - DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months - - DURAVYU continues to demonstrate favorable safety and tolerability profile with... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,500 | +4,97 % | Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| OPKO HEALTH | 1,154 | -2,52 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results | MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights... ► Artikel lesen | |
| EXSCIENTIA | 4,240 | -1,40 % | Exscientia plc: Exscientia Business and Financial Update for the Full Year 2023 | Exscientia plc (Nasdaq: EXAI)
Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 79,50 | 0,00 % | Ligand Pharmaceuticals Inc Q1 Profit Increases, beats estimates | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc (LGND) revealed a profit for its first quarter that increased from the same period last year and beat the Street estimates.The company's earnings... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 103,60 | +1,77 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference | DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference... ► Artikel lesen | |
| ROYALTY PHARMA | 26,310 | +0,92 % | Royalty Pharma plc: Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab | Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma's development-stage portfolio... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 14,605 | -1,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update | Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of... ► Artikel lesen | |
| CATALENT | 51,97 | +0,29 % | Catalent, Inc. Reports Third Quarter Fiscal 2024 Results | SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial... ► Artikel lesen | |
| SOLIGENIX | 0,399 | -1,75 % | SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results | PRINCETON, N.J., May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products... ► Artikel lesen | |
| TALPHERA | 0,937 | -1,88 % | Talphera, Inc.: Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update | Company rebranding and corporate transformation to Talphera completed in Q1 2024
First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission... ► Artikel lesen | |
| AYTU BIOPHARMA | 2,900 | -4,61 % | Aytu BioPharma, Inc.: Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 | DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial... ► Artikel lesen |
Das Unternehmen OMNIAB INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,41 % bei einem Aktienkurs von 4,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
